Vasily Isakov Selected Research

Infections

1/2020	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial.
2/2019	Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
1/2019	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
5/2018	Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.
3/2018	Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
1/2018	Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
12/2017	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
1/2017	Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
2/2016	Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia.
1/2016	Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vasily Isakov Research Topics

Disease

10	Infections 01/2020 - 01/2016
7	Chronic Hepatitis C 01/2019 - 03/2014
4	Fibrosis (Cirrhosis) 02/2019 - 01/2016
2	Hepatitis C 11/2022 - 01/2018
2	Coinfection 03/2021 - 03/2018
1	Liver Diseases (Liver Disease) 10/2019
1	Virus Diseases (Viral Diseases) 01/2019
1	Gastroesophageal Reflux (GERD) 06/2018
1	Reinfection 01/2017
1	Viremia 01/2017
1	Anemia 02/2016
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2006
1	Crohn Disease (Crohn's Disease) 03/2006

Drug/Important Bio-Agent (IBA)

4	Antiviral Agents (Antivirals)IBA 11/2022 - 01/2017
4	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 01/2016
3	grazoprevirIBA 01/2020 - 05/2018
3	elbasvirIBA 01/2020 - 05/2018
2	sofosbuvir drug combination ledipasvirIBA 03/2021 - 03/2018
2	InterferonsIBA 02/2019 - 01/2018
2	SofosbuvirIBA 01/2017 - 01/2016
1	dimemorfan (AT 17)IBA 10/2019
1	Dietary Fiber FDA Link 06/2018
1	Psyllium (Metamucil)IBA 06/2018
1	ombitasvirIBA 01/2018
1	paritaprevirIBA 01/2018
1	dasabuvirIBA 01/2018
1	Ritonavir (Norvir)FDA Link 01/2018
1	daclatasvirIBA 12/2017
1	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 12/2017
1	asunaprevirIBA 12/2017
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Erythropoietin FDA Link 02/2016
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 02/2016
1	telaprevirIBA 03/2014
1	CytokinesIBA 03/2006
1	C-Reactive ProteinIBA 03/2006
1	p38 Mitogen-Activated Protein KinasesIBA 03/2006
1	doramapimodIBA 03/2006

Therapy/Procedure

3	Therapeutics 01/2020 - 01/2017
1	Retreatment 01/2017
1	Aftercare (After-Treatment) 01/2017
1	Drug Tapering 02/2016